CAR T cell therapies for diffuse midline glioma - ScienceDirect
Diffuse midline glioma (DMG), a fatal pediatric CNS cancer, resists surgical removal and sees temporary benefits from radiotherapy, with a median survival of 9–11 months. Its 'cold' tumor immune microenvironment, characterized by immunosuppressive myeloid cells and low lymphocyte infiltration, necessitates novel therapies like CAR T cell treatments, currently under clinical assessment for DMG.
Reference News
Diffuse midline glioma (DMG), a fatal pediatric CNS cancer, resists surgical removal and sees temporary benefits from radiotherapy, with a median survival of 9–11 months. Its 'cold' tumor immune microenvironment, characterized by immunosuppressive myeloid cells and low lymphocyte infiltration, necessitates novel therapies like CAR T cell treatments, currently under clinical assessment for DMG.